Theravance Biopharma Inc
Theravance Biopharma Inc is a biopharmaceutical company focused on developing innovative medicines for the treatment of serious diseases.
Price history of Theravance Biopharma Inc
Price history of Theravance Biopharma Inc
Performance & Momentum
Theravance Biopharma Raised to $17 Despite Doubts
B. Riley raised its price target on Theravance Biopharma to $17 from $14, while maintaining a Neutral rating. The broker pointed to the final settlement of the dispute with MannKind, which secures exclusivity for certain products and provides greater visibility into part of future revenue. Despite this positive signal, the backdrop remains fragile for TBPH. The stock has fallen sharply in recent months after the failure of a flagship drug in late-stage trials, forcing the company to rethink its strategy and restructure its pipeline. The shares could therefore remain volatile, caught between occasional analyst support and lingering uncertainty over growth.
Strategic Analysis
Theravance Biopharma Inc • 2026
Theravance Biopharma is a U.S. niche biopharmaceutical company focused on the development and commercialization of treatments, with a strong emphasis on respiratory diseases. Its positioning relies on a combination of targeted R&D and the monetization of therapeutic assets, allowing it to retain significant value-creation potential while maintaining a more specialized footprint than large pharmaceutical groups.
- Focused expertise in respiratory care, a therapeutic area where specialization can create value
- Strong recent performance profile, suggesting renewed market interest in the stock
- Ability to attract analyst attention despite a mixed stock market history
- Still limited visibility on the durability of the pipeline and the conversion of clinical progress into recurring revenue
- Uneven stock market history, with periods of underperformance that highlight the share’s sensitivity to execution risk
Momentum is clearly favorable and reflects a constructive market trend, with buying interest still clearly present. The recent upward revision in the stock despite lingering doubts shows that the story still has catalyst-driven appeal, but also that valuation is being closely watched. Strategically, this supports a positive medium-term view, while keeping in mind that market confidence will depend primarily on the company’s ability to confirm its operational and clinical progress.
Similar stocks to Theravance Biopharma Inc
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
